Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Glioblastoma 1Bone Marrow Diseases 1

Interventions

Azacitidine 23fludarabine phosphate 17Cyclophosphamide 16Decitabine 12Cytarabine 11Peripheral Blood Stem Cell Transplantation 10Whole-Body Irradiation 9Mycophenolic Acid 9Filgrastim 8Tacrolimus 7Cyclosporine 7venetoclax 6decitabine and cedazuridine drug combination 6fludarabine 5Carboplatin 5sargramostim 4Vorinostat 4Specimen Handling 4Sirolimus 4Radiotherapy 4Injections 4Cyclosporins 4Clofarabine 4Busulfan 4ruxolitinib 3cedazuridine 3aldesleukin 3Topotecan 3Melphalan 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Chronic × sabatolimab × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡